Balchem Corporation announced strong financial results for Q3 2026, with net sales rising 8.6% to $290.7 million and net earnings increasing 16% to $46.7 million. Adjusted EBITDA reached a record $80.3 million, supported by growth across all three business segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The company also generated $57.9 million in free cash flow and repurchased $28 million in stock during the quarter. Balchem's leadership remains optimistic about continued strategic growth and innovation in health and nutrition sectors.
Balchem Corporation's Q3 2026 financial results provide context for readers. For those following the health sector, here is Pluang's market snapshot as of Oct 23, 2026 17:41 WIB: out of 150 priced US health stocks, 42 rose and 97 fell. Notable movers include HRTX at USD 0.30 with a 1-day change of +2.97%, BRKR at USD 56.00 down 2.29%, and INO at USD 0.86 up 2.09%.
Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...
Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...
Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...
ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...
eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...
